Game-changing’ treatment for relapsed multiple myeloma added to the CDF

People with relapsed multiple myeloma who have had one previous therapy will be able to access another innovative treatment option, daratumumab, through the Cancer Drugs Fund. Multiple myeloma is a common form of blood cancer with approximately 5,700 cases diagnosed each year in the UK. It is estimated that 2,900 people will be eligible for treatment with daratumumab each year while it is available through the Cancer Drugs Fund. In the evidence considered by the independent committee, daratumumab (Darzalex, Janssen-Cilag), used in combination with bortezomib plus dexamethasone, extended the length of time people live before their disease progresses by 18